Evidence map›Paper›PMID 36400019›Full record

ArticleCancer cell2022

Understanding NSCLC, one cell at a time.

Iván Ballesteros, Daniela Cerezo-Wallis, Andrés Hidalgo

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Iván BallesterosArea of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.
Daniela Cerezo-WallisVascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Andrés HidalgoArea of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; Vascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: ahidalgo@cnic.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancers are very heterogeneous, a feature that in part emanates from the tumor microenvironment. In this issue, Salcher et al. provide a comprehensive analysis of hundreds of patients with non-small cell lung cancer (NSCLC) at the single-cell level to discover extreme immune diversity and define neutrophil populations associated with treatment outcome.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansTumor Microenvironment

Identifiers

PMID36400019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.